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Abstract                      
Introduction: Helicobacter pylori (H. pylori) infections occur in about 50% of the world 
population and have a main role in the creation of peptic ulcer and gastric cancers. We aimed 
to evaluate the effectiveness of two treatment regimens on the eradication of H. pylori and its 
complications among peptic ulcer patients.  
Materials and methods: By a clinical trial, patients with peptic ulcer showing an infection 
compliance of more than 80%, confirmed by biopsy, were entered into the study and were 
randomly divided in two groups. Group A was treated by medical regimen of Amoxicilline, 
Bismot, Omeperasol and Furazolidone (ABOF) and group B by medical regimen of 
Amoxicilline, Bismot, Omeperasol and Clarithromycin (ABOC) for two weeks. In the next 
step, both groups were treated by only Omeperasol for two weeks and finally, the infection 
rate of H. pylori was investigated by urea breath testing among both groups. 
Results: Among the 137 registered patients, 17 were unable to continue. The mean age of 
patients in group A, was 36.1 years and for group B, was 40.1 years. The rate of infection 
eradication in group A was 38.3% and in group B was 53.3% (P= 0.07). The most common 
symptoms among patients in group A were a bad taste mouth (80%) and headache (70%) and 
in the group B were headache (62%) and a bad taste mouth (60%) respectively. 
Conclusion: ABOF regimen compared to ABOC, showed a lower rate of infection 
eradication and also more complications for patients and the ABOC was considered as the 
preferred regimen.  
Keywords: Peptic ulcer, Helicobacter pylori, Eradication, Furazolidone, Clarithromycin 
Introduction 
The usefulness of Helicobacter pylori (H. 
pylori) eradication for the treatment of 
peptic ulcer is widely recognized, and 
short-term concomitant triple therapy 
using a proton pump inhibitor (ppi) and 
two types of antibiotic is the most popular 
treatment regimen. H. pylori are the 
important cause of gastritis, peptic ulcer 
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disease and a major risk factor of gastric 
cancer (1).  The global eradication success 
of standard triple regimen used for H. 
pylori infection has declined in recent 
years (2). The rate of re-infection after one 
year of treatment in Iran is about 16.4% 
which spot to the sub-optimal treatment 
regimens (3). Dependable extirpation of H. 
pylori infection significantly helps to 
manage these diseases. Any success on the 
infection eradication depends on many 
factors including compliance, antibiotic 
resistance, and adequate dosing of proton 
pump inhibitor (PPI) that provides 
adequate acid suppression. The standard 
therapeutic regimen currently available 
consists of a 3 antibiotics (amoxicillin, 
clarithromycin, and metronidazole), and an 
acid suppressive medication (4). However; 
bacterial resistance to metronidazole and 
increasing resistance to clarithromycin 
have prompted a search for alternative 
therapies (5-7). A useful regimen in one 
geographical area may not be effective in 
another area. The subject of cost is another 
complicated choice, especially in 
developing and underdeveloped countries. 
In addition, the high cost of many drugs 
such as quinolones and clarithromycin, are 
deterrent factors for their use in 
developing countries (8). Furazolidone is a 
relatively new medication with a low 
intestinal absorption rate which is widely 
available and inexpensive in developing 
countries. Furazolidone is a synthetic 
nitrofuran with a broad spectrum of 
antimicrobial activities used in the 
treatment of bacterial infections in humans 
(9). Furazolidone has been used more than 
20 years in China for the treatment of 
peptic ulcer as the single therapeutic agent 
(10). In recent years, a number of clinical 
trials have demonstrated furazolidone as a 
suitable drug for the treatment of H. pylori. 
There are some limited reports of 
resistance to furazolidone (11, 12). 
Clarithromycin is another medication 
which accompanied with other drugs as 
the first line regimen for the treatment of 
H. pylori, particularly when the resistance 
to this drug is less than 15 to 20% (13). 
Clarithromycin is an important antibiotic 
used for the treatment of H. pylori 
infections, and the main factor of treatment 
failure is drug resistance. Clarithromycin 
acts by binding to the peptidyltransferase 
region of 23S rRNA and inhibits protein 
synthesis (14) and is recognized as the key 
antibiotic for H. pylori treatment since it 
has showed the most powerful bactericidal 
effect in vitro compared to the effects of 
other available antibacterial agents (15). 
Unfortunately, the rate of resistance to 
clarithromycin is increasing world-wide, 
and the level of this resistance varies 
between different geographical regions 
(16). The concurrent presence of H. pylori 
and non-steroidal or anti-inflammatory 
drugs has been considered as a damaging 
factor to the gastro duodenal mucosa (17). 
Low socio-economic and educational 
levels, poor socioeconomic conditions, 
living in a family with a high number of 
siblings, and use of external water have 
been identified as risk factors for infection 
onset. The infection persists virtually long-
life if not opportunely treated. Therapy 
failure depends on several factors that can 
be divided into bacterial and host origin. 
Treatment-speciﬁc descriptions including 
manufacturer advices such as doses, 
duration of use as well as methods to 
detect the infection are the effective factor 
in the treatment of infection (18). 
Materials and methods 
By a clinical trial, all peptic ulcer patients 
attending to Ilam gastroenterology clinics 
and having an infection compliance of 
more than 80%, confirmed by biopsy, 
were entered into the study. Excluding 
criteria were; age less than 18years, 
involving with other concurrent severe 
diseases, previous history of H. pylori , 
stomach surgery, antibiotic sensitivity, 
application of proton pomp inhibitors or 
NSAID during past month, stomach cancer  
and any report of  previous non completion 
treatment period. 137 patients with 
confirmed H .pylori were entered into the 
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study and were randomly divided in two 
groups of A and B . 
Group A was treated by medical regimen 
of Amoxicilline (1 gr BD), Bismot sub 
citrate (240mg BD), Omeperasol (20mg 
BD) and Furazolidone (200mg BD) for 
two weeks and group B was also treated 
by the same regimen except for 
Furazolidone which was substituted by 
Clarithromycin (500my BD). In the next 
step, both groups were treated by only 
Omeperasol for two weeks and finally, the 
infection rate of H. pylori was investigated 
by urea breath testing (UBT) among both 
groups. Before UBT, all patients were 
NPO for 6 hours and negative UBT was 
considered if 14Co2 <50dpm was reported 
during 10 minutes (eradication of H. 
pylori) and any report of 14Co2 more than 
200dpm was considered as positive UBT 
(existence of H. pylori). 
Statistical analysis 
Using SPSS 16 both qualitative and 
quantitative variables were analyzed. 
Quantitative variables were expressed as 
mean ± standard deviation (SD) and 
qualitative variables were described by 
percentage. Chi-squared or Fisher exact 
tests were used to compare the effects of 
treatment in groups A and B, 
appropriately. Independent T-test was used 
for comparison of quantitative variables.  
A p-value <0.05 was considered as 
significant. 
This study was confirmed by the research 
ethics committee of Ilam University of 
medical sciences, conform to the last 
update of Helsinki Declaration and all 
patients completed a consent form for 
entering into the study. Patients were also 
able to exit freely from the study.     
Results  
Totally 137 patients had the criteria to 
enter in the study and due to 
noncompliance, 17 patients (5 from group 
A and 12 from group B) were exited from 
the study. Finally, 120 patients (each 
group 60) who completed the treatment 
regimen were analyzed (Figure 1). Both 
medical complications and response to 
drug regimens were investigated. 
Group A included 30 male and 30 female 
and group B included 23 male and 37 
female with a mean age of 36.1 yrs for 
group A and 40.1 yrs for group B. 
Negative urea breath test (UBT) was 
reported for 32 patients (53%) in group B 
(ABOC) and for 23 patients (38%) in 
group A (ABOF) (P=0.07) (Tables 1-2). 
 
 Figure 1. The flowchart of selected participants in different groups. 
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Table 1. Frequency rate of infected participants after 1 month in different groups 
according to the UBT results. 
Total Non eradicated Eradicated Variable 
60 (50) 37 (61.7) 23 (38.3) Group A   
60 (50) 28 (46.7) 32 (53.3) Group B   
120 (100) 65 (54.2) 55(45.8) Total 
Data are shown as number or percent.  
 
          Table 2. Frequency rate of side effects reported by participants among both group. 
P value Group B Group A Variable 
0.22 37 (61.7) 42 (70) Headache 
0.07 28 (50) 37 (61.7) Vomiting 
0.35 32(53.3) 29(48.3) Diarrhea 
0.22 35 (58.3) 40 (66.7) Abdominal pain 
0.29 32 (53.3) 36 (60) Stool colour change 
0.18 10 (16.7) 15 (25) Skin sensitivity 
0.01 36 (60) 48 (80) Bad taste mouth 
0.29 9 (15) 6 (10) Nausea 
                        Data are shown as number or percent. 
 
Headache (61.7%), nausea (46.7%), 
vomiting (15%), diarrhoea 
(53.3%),abdominal pain (58.3%), melena 
(53.3%) and dermal sensitivity (16.7%) 
were reported among patients in group B 
and the rates of involved patients in group 
A for the above mentioned medical 
complications were 70%, 61.7%, 10%, 
48.3%, 66.7%, 60% and 25% respectively, 
all statistically non-significant. There was 
a significant difference between patients in 
the group B (60%) compared to those in 
the group A (80%) for bad flavor of the 
mouth as a medical complication (p<0.01). 
The prevalence of side effects due to 
treatment regimen was generally 37.5% 
among patients in group A and 22.1% 
among those in group B. The total 
treatment expenditure for group B was 2.3 
times more than that for group A. 
Discussion  
The discovery of H. pylori as the 
promoting factor of many diseases caused 
a high attempt by the researchers to find a 
comprehensive method of therapy for this 
agent. Many people still attribute 
symptoms of dyspepsia to an ulcer, and 
believe that ulcers are caused by diet, 
stress, and lifestyle factors; however, it is 
now clear that eradication of H. pylori is 
very effective on the treatment of this 
illness. It has been accepted that H. pylori 
infection is the major cause of peptic ulcer, 
MALT lymphoma and gastroesophageal 
reflux disease (GERD), and the number of 
suggested regimens for its treatment and 
eradication are increasing. In the recent 
studies, triple therapy with omeprazole, 
amoxycillin and clarithromycin has been 
reported as an effective regimen. Most 
international guidelines for H. pylori 
eradication point to the standard triple 
therapy including the combination of two 
antibiotics and a proton-pomp inhibitor 
(PPI) for at least 7 days, but the success 
rates using these triple therapies have 
fallen to 75%(19). To overcome H. pylori 
treatment limitations, furazolidone-based 
treatments have been suggested in 
developing countries by the World 
Gastroenterology Organization guidelines 
(8). Furazolidone-based regimens usually 
achieve low eradication rates. Only a high-
dose regimen improves the cure rate, but 
increases the incidence of severe side 
effects simultaneously (20). Although the 
current study did not show a significant 
difference between the two medical 
regimens of ABOF and ABOC, but the 
ABOF showed a lower rate of eradication 
as well as higher complications for 
patients. According to these results, the 
ABOC was considered as the preferred 
regimen. 
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